Last $48.37 USD
Change Today -0.10 / -0.21%
Volume 5.8M
GSK On Other Exchanges
Symbol
Exchange
OTC US
New York
Xetra
London
Mexico
Frankfurt
As of 8:04 PM 07/31/14 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc-spon adr (GSK) Key Developments

GlaxoSmithKline Denies Plans to Spin Off Consumer Health-Care Division

GlaxoSmithKline plc (LSE:GSK) has no plans to spin off its consumer health-care division, a spokesman said today. While GlaxoSmithKline won’t rule out the possibility of one day shedding the unit, it’s not currently being considered, said Simon Steel. The Financial Times reported the possibility of a spinoff on July 28, 2014.

GlaxoSmithKline May Spin Off Consumer Healthcare Arm

GlaxoSmithKline plc (LSE:GSK) may spin off its consumer health division as it tries to get to grips with increasing competition for its drugs and Chinese bribery allegations. Glaxo may demerge the business, which includes brands such as Aquafresh toothpaste, Panadol painkillers and Horlicks, in time but had no immediate plans, Chief Executive Andrew Witty told the Financial Times. He made clear there were no such plans in the near term but, by raising it as a possibility.

FDA Approves GlaxoSmithKline's Flonase for Over-the-Counter Sale

GlaxoSmithKline announced that the FDA approved Flonase Allergy Relief as an over-the-counter treatment to temporarily relieve hay fever or upper respiratory allergies. The company said Flonase is the first and only over-the-counter nasal spray indicated for relief of all nasal and eye-related allergies including runny nose, sneezing, itchy nose, nasal congestion and itchy and watery eyes.

GlaxoSmithKline Submits Regulatory Application for its Malaria Vaccine Candidate, RTS,S to the European Medicines Agency

Agenus Inc. announced that GlaxoSmithKline has submitted a regulatory application for its malaria vaccine candidate, RTS,S, to the European Medicines Agency (EMA), and it has been accepted for regulatory review. RTS,S contains Agenus' QS-21 Stimulon(R) adjuvant, which is part of GSK's AS01 proprietary adjuvant system. Adjuvants can enhance the immune response when used in combination with antigens in vaccines. The Phase 3 RTS,S vaccine program was conducted at 13 African research centers in eight African countries (Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique, Nigeria, and Tanzania) and included over 16,000 infants and young children. These data have been included to support the regulatory filing. The EMA submission is the first step in the regulatory process toward making the RTS,S vaccine candidate available as an addition to existing tools currently recommended for malaria prevention. An effective vaccine for use alongside other measures, such as bed nets and anti-malarial medicines, would represent an advance in malaria control. If a positive opinion from the EMA is granted, the WHO indicated that a policy recommendation may be possible by the end of 2015. A policy recommendation is a formal review process by WHO designed to assist in the development of optimal immunization schedules for diseases that have a global public health impact, such as malaria. RTS,S is the scientific name given to this malaria vaccine candidate and reflects the composition of this vaccine candidate that also contains the AS01 adjuvant system; RTS,S triggers the body's immune system to defend against the P falciparum malaria parasite when it first enters the human host's bloodstream and/or when the parasite infects liver cells; The vaccine is designed to prevent the parasite from infecting, maturing and multiplying in the liver, after which time the parasite would re-enter the bloodstream and infect red blood cells, leading to disease symptoms. In the Phase 3 efficacy trial, RTS,S was administered in three doses, one month apart.

GlaxoSmithKline plc Declares Second Interim Dividend, Payable on 2 October 2014

The Board of GlaxoSmithKline plc has declared a second interim dividend of 19 pence per share against 18 pence per share for the second quarter of 2013. The equivalent interim dividend receivable by ADR holders is 64.8204 cents per ADS based on an exchange rate of £1/$1.7058. One ADS represents two ordinary shares. The ex-dividend date will be 6 August 2014, with a record date of 8 August 2014 and a payment date of 2 October 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GSK:US $48.37 USD -0.10

GSK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $140.89 USD -2.85
Bayer AG €98.77 EUR +0.37
Novo Nordisk A/S kr255.50 DKK -2.40
PepsiCo Inc $88.10 USD -0.81
Sanofi €79.25 EUR +0.63
View Industry Companies
 

Industry Analysis

GSK

Industry Average

Valuation GSK Industry Range
Price/Earnings 14.6x
Price/Sales 2.8x
Price/Book 11.1x
Price/Cash Flow 14.4x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC-SPON ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.